No­vo Nordisk un­veils $165M buy­out bid for a drug de­liv­ery part­ner on smart in­sulin pens

No­vo Nordisk put in an of­fer to buy out a French med­ical de­vice com­pa­ny with which it has part­nered to de­vel­op new in­jec­tion de­vices in a deal that brings a siz­able drug de­liv­ery group in­to its fold.

At €35 (about $37.00) per share, No­vo Nordisk’s pro­posed deal would val­ue Bio­corp at about €154.4 mil­lion ($165 mil­lion) — a small amount when jux­ta­posed with the large mar­ket for di­a­betes and oth­er chron­ic dis­eases that No­vo be­lieves Bio­corp’s tech­nol­o­gy can help re­shape.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.